ImaginAb snags GE research partnership

Biotech company ImaginAb has locked a research deal with GE Healthcare to develop PET diagnostic imaging agents for cardiovascular disease, the companies said on June 5.

Under the master research agreement, Waukesha, Wis.-based GE Healthcare will collaborate with ImaginAb to utilize the company’s antibody fragment platform to develop targeted molecular diagnostics, centered on imaging high-risk cardiovascular disease. Inglewood, Calif.-based ImaginAb is a biotechnology company that develops engineered antibody fragments for diagnostic imaging and treatment.

Around the web

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.